| HOME >> BIOLOGY >> TECHNOLOGY |
BERKELEY, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Deborah Smeltzer, Vice President and Chief Financial Officer, will present an overview of the company at the UBS 2007 Global Life Sciences Conference in New York, New York on Tuesday, September 25th at 9:30 a.m. Eastern Daylight Savings Time (6:30 a.m. PDST). The presentation will be webcast.
To access the live audio broadcast and the subsequent archived audio recording of the company presentation, please log onto the company's website at http://www.dynavax.com under the "Investors'" section.
ABOUT DYNAVAX
Dynavax Technologies Corporation discovers, develops, and intends to
commercialize innovative TLR9 agonist-based products to treat and prevent
infectious diseases, allergies, cancer, and chronic inflammatory diseases
using versatile, proprietary approaches that alter immune system responses
in highly specific ways. Our TLR9 agonists are based on immunostimulatory
sequences, or ISS, which are short DNA sequences that enhance the ability
of the immune system to fight disease and control chronic inflammation. Our
product candidates include: HEPLISAV, a hepatitis B vaccine in Phase 3;
TOLAMBA(TM), a ragweed allergy immunotherapy; a therapy for non-Hodgkin's
lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1;
and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and
COPD program is partnered with AstraZeneca. The National Institutes of
Health (NIH) partially funds our preclinical work on a vaccine for
influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials
and our preclinical hepati
'/>"/>
| SOURCE Dynavax Technologies Corporation Copyright©2007 PR Newswire. All rights reserved |